

The efficacy and safety of tirofiban versus oral antiplatelet drug therapy in acute ischemic stroke patients with early neurological deterioration

(European Journal of Clinical Pharmacology)

Qian Xiao¹ • Yangbo Hou¹ • Jiwei Cheng¹ • Yinqin Hu¹ • Jie Tao^{1#} • Dan Wu^{2#} • Guoyi Li^{1#}

¹Department of Neurology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

²Department of Radiology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

#Correspondence to: Guoyi Li (lgy_putuo@126.com); Dan Wu (609269120@qq.com); Jie Tao (jietao_putuo@foxmail.com)

Online Resource 2 The efficacy outcomes of different ages in the tirofiban group

Tirofiban group	age≤75 years	age>75 years	Statistic	<i>p</i> value
Patients n	84	23		
NIHSS score before treatment	6(4-8)	5(4-9)	$Z = -0.447$	0.655
NIHSS score at discharge	4(2-6)	4(2-7)	$Z = -0.764$	0.445
NIHSS score difference	-2(-3-0)	-2(-3--1)	$Z = -0.404$	0.686
Decline ratio of NIHSS score	0.40(0-0.57)	0.33(0.13-0.54)	$Z = -0.145$	0.885
NIHSS improvement at discharge			$\chi^2 = 0.811$	0.667
Effective n (%)	52(61.9)	14(60.9)		
Ineffective n (%)	32(38.1)	9(39.1)		
No changes n (%)	24(28.6)	8(34.8)		
Deterioration n (%)	8(9.5)	1(4.3)		
Motor score before treatment	3(2-6)	4(2-7)	$Z = -1.716$	0.086
Motor score at discharge	2(1-4)	3(2-5)	$Z = -2.038$	0.042*
Motor score difference	-1(-2-0)	-1(-2-0)	$Z = -0.304$	0.761
Decline ratio of motor score	0.25(0-0.67)	0.25(0-0.50)	$Z = -0.494$	0.621
Motor improvement at discharge			$\chi^2 = 0.865$	0.649
Effective n (%)	48(57.1)	14(60.9)		
Ineffective n(%)	36(42.9)	9(39.1)		
No changes n (%)	27(32.1)	8(34.8)		
Deterioration n (%)	9(10.7)	1(4.3)		
Functional outcome at 90 days				
mRS 0-1	26(31.0)	4(17.4)	$\chi^2 = 1.646$	0.200
mRS 0-2	55(65.5)	10(43.5)	$\chi^2 = 3.664$	0.056

* $p < 0.05$.